In collaboration with

Acknowledgement of Commercial Support
This activity is supported by an educational grant from Regeneron

Title: Patient-Centered Management of Severe Asthma: A Practical Guide for Primary Care

Release | Expiration: December 12, 2025 – August 28, 2026

Statement of Need:
Biologic therapies targeting IgE, IL-5, IL-4Rα, and TSLP have reshaped the landscape for severe asthma, allowing for personalized, phenotype-driven care. These agents offer options for patients who remain symptomatic despite maximal inhaled therapy. Several biologics are currently approved, with dupilumab and tezepelumab among the most recent additions. This expanded toolkit offers flexibility in treatment selections, yet it can also make decisions more complicated for asthma specialists and primary care providers alike.

 
Primary care physicians are central to early diagnosis, education, and stepwise guideline-based management. Despite this role, primary care physicians often overestimate asthma control, underuse validated tools, and referrals for advanced therapy may be delayed or missed.  When asthma remains uncontrolled, timely referral to specialists is vital. Co-management models facilitate the referral process. For example, the UBIOPRED initiative in Europe established shared protocols for biomarker-driven care across primary and specialty settings. These approaches reduce delays in therapy escalation and support individualized treatment and continuity of care.

Given the ongoing challenges in asthma management and the expanding treatment landscape, connecting asthma experts with primary care providers through structured, collaborative education is essential. This curriculum is intended for primary care physicians and will support them in identifying uncontrolled asthma, applying validated assessment tools, and recognizing when to escalate therapy or refer patients for specialist evaluation and co-management.

Educational Objectives:

IDENTIFY key clinical indicators of uncontrolled asthma and determine when escalation of therapy and referral to a specialist is warranted

UTILIZE validated assessment tools and relevant biomarkers to evaluate asthma control and inform treatment decisions in primary care settings

Target Audience:
Primary Care Physicians (Internal Medicine, Family Medicine, Pediatrics and APPs)

Faculty:

	Karla E. Adams, MD, FAAAAI, FACAAI, FAAP Professor of Pediatrics Uniformed Services University Bethesda, MD Program Director, Allergy and Immunology Fellowship Wilford Hall Ambulatory Surgical Center Lackland Air Force Base, TX
Disclosures	Dr. Adams has no relevant disclosures

Technical Writer:
Lynne Kolton Schneider, PhD

Disclosures
No relevant financial disclosures

Reviewer

Jordana Goldman, MD

Disclosures
No relevant financial disclosures

Accredited Provider Disclosure:
None of the planners, reviewers, and AAAAI and RealCME staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.

Disclosure of Financial Relationships Policy:
AAAAI adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME/CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accredited Provider & Accreditation Statements:
This activity is accredited through AAAAI. 

CME: The American Academy of Allergy Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CE: The American Academy of Allergy Asthma and Immunology (AAAAI) is a Provider approved by the California Board of Registered Nursing, Provider #10704.

Credit Designation Statement:
The AAAAI designates this activity for up to 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use:
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AAAAI and RealCME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact cme@aaaai.org

Method of Participation/Instructions:
Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-assessment and evaluation, and have received a digital copy of your credit certificate.

In order to claim the maximum amount of credit available, you must complete all of the following:

• Baseline/Final Assessments: 30 minutes each for a total of up to 1.00 hour of CME
• Two (2) Self-Study Modules: 15 minutes each for a total of up to 0.50 hour of CME
• Two (2) Live Group Discussion: 45 minutes each for a total of up to 1.50 hour of CME
• Two (2) Group Challenges: 30 minutes each for a total of up to 1.00 hour of CME
• Action Plan (1) development: 30 minutes for a total of 0.50 hour of CME 

Privacy Statement:
The American Academy of Allergy, Asthma & Immunology (AAAAI) takes your privacy seriously. AAAAI will only use your personal information to administer your registration, attendance, and credit claiming/attendance record for this activity, to provide services that you have requested from AAAAI and otherwise as you may expressly consent. A complete copy of AAAAI’s Legal and Privacy Notices, the terms of which are incorporated herein, can be found here.

By providing consent, you are allowing AAAAI to process your personal data. AAAAI will collect and store information you provide in the Registration Forms for the purposes of enabling us to register your attendance at the activity; to assist with administrative, planning and marketing purposes; and to allow the compilation and analysis of statistics relevant to AAAAI. 
 
The information you provide in the Registration Forms, and information provided at any other time during this activity, including without limitation any feedback obtained during the activity, will be used by AAAAI to offer, provide and continue to improve its educational activities and other services. The AAAAI may also use your email address to communicate important information regarding this activity and for marketing purposes for future activities. AAAAI will not otherwise, without your consent, use or disclose your personal information for any purpose unless it would reasonably be expected that such a purpose is related to the offer, provision and improvement of the activity or where such purpose is permitted or required by law. 

I understand that it is my right to withhold consent to the above Privacy and Data Protection Notice, or to withdraw my previous consent at any time. I further understand that without my consent, it is not possible to process my registration/housing request for this activity. Please contact the AAAAI Education Team at (414) 272-6071 if you have any further questions about how this will affect your registration request for this activity.